NK1.1 antibody [PK136] (PerCP-Cy5.5)

Cat# GTX01478-11-100ug

Size : 100ug

Brand : Genetex

Contact local distributor :


Phone : +1 850 650 7790

Anti-NK1.1 antibody [PK136] (PerCP-Cy5.5) used in Flow cytometry (FACS). GTX01478-11

Host

Mouse

Clonality

Monoclonal

Clone Name

PK136

Isotype

IgG2a

Application

FACS

Reactivity

Mouse
Package
100 μg
View product citations for antibody GTX01478-11 on CiteAb
PRODUCT

Summary

The PK136 antibody is specific for mouse NK1.1, a type II transmembrane lectin-like receptor and member of the killer cell lectin-like receptor (KLR) family. NK1.1 is prominently expressed on natural killer (NK) cells, and is correlated with NK cytotoxic effects toward virus-infected cells and tumor cells. NK1.1 is expressed on subsets of NKT cells in certain mouse strains (C57BL/6, FVB/N, and NZB), yet absent from others (AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129). Putative subsets of NK cells and their expression of NK1.1 antigen are of continuing interest, including NK1.1+/CD117+ (c-Kit) cells reported to be immunosuppressive for CD8+ T cells in a mechanism involving PD-1 and PD-L1. The PK136 antibody may be used for detection of NK1.1 expression on mouse strains including CE, B6, NZB, C58, Ma/My, ST, SJL, and FVB. The antibody is reported to react with an epitope common to NKR-P1B and NKR-P1C alloantigenic forms of NK1.1.

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Recommended Dilution
FACS Assay dependent
Not tested in other applications.

Calculated MW

25 kDa. ( Note )

PROPERTIES

Form

Liquid

Buffer

10mM NaH₂PO₄, 150mM NaCl, 0.1% Gelatin

Preservative

0.09% Sodium azide

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE. Protect from light.

Concentration

0.2 mg/ml (Please refer to the vial label for the specific concentration.)

Purification

Purified by affinity chromatography
From tissue culture supernatant

Conjugation

Peridinin-chlorophyll proteins-Cyanine5.5 (PerCP-Cy5.5)

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

TARGET

Cellular Localization

Membrane

Database

DATA IMAGES

Anti-NK1.1 antibody [PK136] (PerCP-Cy5.5) used in Flow cytometry (FACS). GTX01478-11

GTX01478-11 FACS Image

FACS analysis of mouse C57Bl/6 splenocytes using GTX01478-11 NK1.1 antibody [PK136] (PerCP-Cy5.5).
Right panel : co-stained with NK1.1 antibody [PK136] (PerCP-Cy5.5) and Mouse CD3e antibody (FITC)
Left panel : co-stained with isotype control and Mouse CD3e antibody (FITC)
antibody amount : 0.25 μg (5 μl)

Clone Reference

2019; Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
2018; Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
2012; Lyn-dependent signaling regulates the innate immune response by controlling dendritic cell activation of NK cells.
2011; Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
2011; The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.
Submit a Reference

REVIEW

There are currently no reviews for NK1.1 antibody [PK136] (PerCP-Cy5.5) (GTX01478-11). Be the first to share your experience with this product.
Clone Reference
2019; Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
2018; Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
2012; Lyn-dependent signaling regulates the innate immune response by controlling dendritic cell activation of NK cells.
2011; Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
2011; The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.
2010; Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes.
2008; Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways.
2005; Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptors.
2001; Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
SDS
Sodium Azide.pdf